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Crystal Structures of a Ligand-free and
Malonate-Bound Human Caspase-1: Implications
for the Mechanism of Substrate Binding
1997; Rao et al., 1996; Ueki et al., 2001; Winter et al.,
2001) and that the enzyme’s activation and apoptosis
are not necessarily linked, albeit these two processes
may occur concomitantly in many inflammatory condi-
tions (Zeuner et al., 1999). All in all, extensive studies of
Michael J. Romanowski,1,* Justin M. Scheer,2
Tom O’Brien,2 and Robert S. McDowell3
1Department of Structural Biology
2 Department of Biology
3 Department of Chemistry
Sunesis Pharmaceuticals, Inc. caspase-1 in inflammation and apoptosis validated the
enzyme as an attractive drug target, the inhibition of341 Oyster Point Boulevard
South San Francisco, California 94080 which may alleviate a variety of human ailments (O’Brien
and Lee, 2004).
Caspase-1 is expressed as a procaspase-1 zymo-
gen that is processed into a catalytically competent formSummary
through autoproteolysis induced by protein oligomeriza-
tion in vitro (Yang et al., 1998), but may require casp-Caspase-1, a mediator of the posttranslational pro-
ase-5 for efficient activation in vivo (Kang et al., 2000;cessing of IL-1 and IL-18, requires an aspartic acid
Martinon et al., 2002; Wang et al., 1998). The cleavagein the P1 position of its substrates. The mechanisms
reaction removes the 119-residue propeptide and an 18-of caspase-1 activation remain poorly understood de-
residue sequence that separates the large (p20; residuesspite numerous structures of the enzyme complexed
120–298) and small (p10; residues 317–404) subunits ofwith aspartate-based inhibitors. Here we report a crys-
the mature enzyme. The functional form of caspase-1tal structure of ligand-free caspase-1 that displays
is believed to be a tetramer composed of two p20/p10dramatic rearrangements of loops defining the active
heterodimers (Gu et al., 1995; Wilson et al., 1994). In vitro,site to generate a closed conformation that is incom-
caspase-1 undergoes inactivating autolysis at high con-patible with substrate binding. A structure of the en-
centrations by cleaving the p10 subunit after Asp381zyme complexed with malonate shows the protein in
(Dang et al., 1996) and targeting other Asp residues inits open (active-site ligand-bound) conformation in
the p20 subunit, although not as efficiently as Asp381which malonate reproduces the hydrogen bonding
(unpublished data).network observed in structures with covalent inhibi-
Given the importance of caspases in inflammatorytors. These results illustrate the essential function of
and apoptotic processes, there has been an intensethe obligatory aspartate recognition element that
effort to characterize the family members structurally.opens the active site of caspase-1 to substrates and
Most of the structures presented to date show proteinsmay be the determinant responsible for the conforma-
bound to cofactors or inhibitors: caspase-1 (PDB ID:tional changes between ligand-free and -bound forms
1BMQ, 1IBC, 1ICE, 1M72, 1RWK, 1RWM, 1RWN, 1RWO,of the enzyme, and suggest a new approach for identi-
1RWP, 1RWV, 1RWW, 1RWX, 1SC1, 1SC3, and 1SC4),fying novel aspartic acid mimetics.
caspase-2 (PDB ID: 1PYO), caspase-3 (PDB ID: 1CP3,
1GFW, 1I3O, 1NME, 1NMQ, 1NMS, 1PAU, 1QA8, 1QX3,
Introduction 1RE1, 1RHJ, 1RHK, 1RHM, 1RHQ, 1RHR, and 1RHU),
caspase-7 (PDB ID: 1F1J, 1I4O, 1I51, 1K86, 1K88, 1KMC,
Caspase-1 (also known as interleukin 1-converting en- 1GQF, 1SHJ, and 1SHL), caspase-8 (PDB ID: 1F9E, 1I4E,
zyme or ICE) is a member of a family of aspartate-spe- 1QDU, and 1QTN), and caspase-9 (PDB ID: 1NW9 and
cific cysteine proteases. It was originally identified as a 1JXQ). A recently solved structure of caspase-9 revealed
monocyte-specific endopeptidase responsible for the two vastly different active-site conformations within
posttranslational processing of the proinflammatory cy- each dimer in the asymmetric unit (PDB ID: 1JXQ) (Rena-
tokine interleukin 1 (IL-1) (Cerretti et al., 1992; Howard tus et al., 2001). In caspase-9, the two dimeric domains
et al., 1991; Thornberry et al., 1992), a major mediator may not be equivalent, since two active catalytic do-
of inflammatory disease such as rheumatoid arthritis. mains would create a severe steric clash with each other
Soon thereafter, caspase-1 was shown to process in- and likely prevent the formation of a functional tetramer.
terleukin-18 (IL-18), a cytokine structurally similar to IL-1 In mature caspase-7, rearrangements of the active-site
that is involved in T cell activation (Dinarello, 1998). loops between ligand-bound and -unbound forms of
Many of the caspase family members are activated the enzyme, although qualitatively different from those
during programmed cell death, and their proteolytic ac- observed in caspase-9, lead to a closure of the active
tivity is a central biochemical feature of the apoptotic site in the absence of a ligand (PDB ID: 1K86) (Chai et
process (Solary et al., 1998). Initial studies of caspase-1 al., 2001). There is, however, an indication that not all
knockout mice revealed that the enzyme did not play a caspases undergo significant structural rearrangements
significant role in the development of apoptosis (Kuida upon binding of an inhibitor or substrate. A crystal struc-
et al., 1995; Sanna et al., 2002). More recent studies ture of mature caspase-3 crystallized in the presence
demonstrated, however, that caspase-1 may perform of an inhibitor, in which the inhibitor appears not to have
both pro- and antiapoptotic functions (Beyaert et al., bound the active site (PDB ID: 1QX3) (Ni et al., 2003),
revealed conformations closely resembling those of ma-
ture caspase-3 seen in complexes with peptide inhibi-*Correspondence: romanom@sunesis.com
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tors. It is nonetheless unclear if the presence of a potent The most dramatic conformational change occurs
within the 15-residue L3 in the small subunit containinginhibitor of caspase-3 in the crystallization buffer in-
duced a catalytically impeded active site in the enzyme Arg341, a residue in the P1 specificity pocket, a largely
positively charged region of the active site containingand whether the enzyme would crystallize in a different
form under inhibitor-free conditions. an oxyanion hole with the active-site thiol group and
aspartate specificity residues contributed by both theTo better understand the role of the critical aspartate
recognition element in controlling the conformation of the small and large subunits of the mature enzyme (Figures
1A and 1D). The rearrangement from the ligand-freeactive site, we determined the structures of ligand-free
caspase-1, the enzyme bound to a malonate molecule, to ligand-bound form enables caspase-1 to transfer
Arg341 from the surface of the protein into the S1 regionand ligand-free caspase-1 crystallized in the presence
of malonate after soaking malonate out. The structures of the active site and makes the side chain atoms of this
residue available for the required H-bonding interactionsenabled us to identify three regions of the active site
that undergo dramatic conformational rearrangements with the aspartic acid portion of the substrate. Hence,
instead of only a simple angular shift at the anchor pointsfrom a ligand-free to ligand-bound form and to discover
a conformation intermediate between the two forms. defined by bonding residues Cys331 (whose carbonyl
oxygen H-bonds to the amino nitrogen of Thr388: 2.8 A˚Surprisingly, binding of the low molecular mass malo-
nate molecule in the P1 specificity pocket of the en- in the ligand-free enzyme and 2.9 A˚ in the ligand-bound
protein) and Ser347 (whose carbonyl oxygen is stabi-zyme’s active site is sufficient to remodel the active site
into a conformation capable of accepting and recogniz- lized by H-bonding interactions with the amino groups
of two residues in the p10 subunit: 3.0 A˚ to Gly351 Ning substrates. This result explains the absolute require-
ment for an aspartic acid in the P1 position of substrates and 3.5 A˚ to Ile350 N in the ligand-bound enzyme, 3.1 A˚
to Gly351 N and 3.2 A˚ to Ile350 N in the ligand-freeand suggests that aspartate is the “key” that locks the
enzyme in the catalytically competent conformation. Ad- enzyme), L3 undergoes a complete reorganization com-
posed of a translational shift accompanied by an angularditionally, the results of this work extend significantly our
understanding of the dynamic mechanism of substrate movement of the entire loop (see Supplemental Movie
S1). This transition from the ligand-free to ligand-boundbinding by caspase-1 and may facilitate a more robust
drug discovery effort aimed at finding suitable replace- form of caspase-1 not only rotates Arg341 by approxi-
mately 180 from the surface of the protein moleculements for the aspartate functionality on small-molecule
caspase-1 inhibitors. into the oxyanion hole of the S1 region, but also transfers
the hydrophobic Trp340 from the surface of the protein
into the S2 region of the active site. Prolines 335 and
Results and Discussion 343 serve as pivot points on which the repositioning of
the loop takes place. The concomitant angular move-
Structure of an Active Ligand-free Caspase-1 ment shifts L3 by approximately 4.9 A˚, placing the loop
Containing a Cys285→Ala Mutation over the catalytic groove in the ligand-free enzyme and
In the ligand-free form of the catalytically inactive, rendering the groove inaccessible to the bulky scaffold
Cys285→Ala mutant version of caspase-1, whose struc- of a substrate or a small-molecule inhibitor. The closure
ture was solved to 2.6 A˚ resolution, the catalytic groove of the active site is not complete, however, as there is
remains inaccessible to the substrate. Three segments ample space in the S1 region of the site to allow binding
with well-defined boundaries undergo dramatic confor- of the obligatory aspartate recognition element of the
mational changes from a ligand-free to ligand-bound ligand. It is possible that binding of the aspartic acid
form to remodel the active site and make it available for moiety of the substrate to the P1 specificity pocket is the
the binding of a substrate or a small-molecule inhibitor. first critical binding event that enables reorganization
These stretches of amino acids span residues 285–290 of the active site into an open, catalytically competent
(Cys-Arg-Gly-Asp-Ser-Pro; loop 2 or L2) in the p20 sub- conformation.
unit (Figure 1C; see Supplementary Figures S1A and S1B Smaller conformational changes occur in L2, which
at http://www.structure.org/cgi/content/full/12/8/1361/ contains the active-site Cys285. Gln283, which provides
DC1), 332–346 (Ser-Ser-Thr-Pro-Asp-Asn-Val-Ser-Trp- a H-bond donor to one of the aspartate’s carboxylate
Arg-His-Pro-Thr-Met-Gly; loop 3 or L3) (Figures 1D; and oxygens in the ligand-bound form (Figure 2), adopts a
Supplemental Figures S1C and S1D), and 381–385 (Asp- different rotamer in the ligand-free enzyme (Figure 1C).
Gly-Arg-Ala-Gln; loop 4 or L4) (Figures 1E; and Supple- In ligand-free caspase-1, Gln283 N2 H bonds to Ser347
mental Figures S1E and S1F) in the p10 subunit. Al- O (2.7 A˚) and serves as a new anchor point for the
though the loops were placed in the electron density newly rearranged loop that starts at Ala285 (Cys285 in
with a high degree of confidence, the average tempera- the wild-type protein); in the ligand-bound protein, the
ture factors for these segments are approximately 50% distance between the same atoms of Gln283 and Ser347
higher than for other protein atoms: 82.2 for L2, 73.7 for is 3.9 A˚. Ala285 then takes a 43 turn away from Cys285
L3, 78.7 for L4, 51.4 for protein atoms, and 51.4 for water in the ligand-bound enzyme, which results in a 1.4 A˚
molecules, suggesting that the loops are flexible in the separation between the residue’s C (Figure 1C). The
ligand-free enzyme. Concomitant with the rearrange- potential salt bridge between Arg286 and Glu390
ments of the loops is the reorganization of the hydrogen (Arg286 N1-Glu390 O1  2.7 A˚, Arg286 N2-Glu390
bonds that stabilize the ligand-free conformation as O1  2.9 A˚) and H-bonding interactions formed be-
compared with those in the structure of caspase-1 in tween Arg286 and Ser333 (Arg286 N-Ser333 O  3.2 A˚,
and Arg286 N2-Ser333 O  3.2 A˚) in the ligand-boundcomplex with a peptide inhibitor (1ICE).
Crystal Structure of Ligand-free Caspase-1
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Figure 1. Analysis of Structural Rearrangements in the Active Site of Caspase-1 during Transition from Ligand-free to Ligand-Bound Conforma-
tions
Inhibitor-bound proteins are shown as green cartoons or sticks, ligand-free forms are purple or pink. Broken yellow lines indicate distances
between the corresponding  carbons.
(A) Overlay of peptide inhibitor-bound (PDB ID: 1ICE) and ligand-free caspase-1.
(B) Overlay of caspase-1 in complex with a peptide inhibitor (PDB ID: 1ICE) and the enzyme crystallized in the presence of malonate after
removal of the ligand.
(C) Loop 2 of inhibitor-bound and ligand-free caspase-1.
(D) Loop 3 of inhibitor-bound and ligand-free caspase-1. L3 shifts approximately 4.9 A˚ over the active site in the absence of an inhibitor.
(E) Loop 4 of inhibitor-bound and ligand-free caspase-1.
Structure
1364
protein are no longer present in ligand-free caspase-1.
Instead, the amino group nitrogen of Arg286 H bonds
to the carbonyl oxygen of Ser333 (3.5 A˚), and Arg286
N2 may H-bond weakly to Asp288 O2 (in the ligand-
bound protein, the side chains of Arg286 and Asp288
point away from each other at a 180 angle). Asp288
C in the ligand-free enzyme rotates 83 relative to the
corresponding atom in the ligand-bound enzyme, and
its side chain faces away from the catalytic groove. The
conformational changes in L2 suggest that this segment
of the protein performs a dual function: (1) it provides
a subset of atoms for interactions with the S1 binding
element of the substrate and catalysis proper, and (2)
it stabilizes the conformation of both the ligand-free and
bound enzyme primarily through H-bonding interactions
with residues from and around L4.
The least drastic conformational changes observed
in the crystal structure of the ligand-free enzyme occur
in the 5-residue-long loop 4 in the p10 subunit (Figures
1A and 1E). The salient movement in L4 involves a small
angular shift of the loop toward L3 that enables Arg383
N1 to H bond to Asp336 O2 in L3 (2.7 A˚). The distance
between Arg383 C in the ligand-free enzyme and
Arg383 C in the ligand-bound protein is 2.5 A˚. More-
over, Arg383 in the ligand-free enzyme adopts a rotamer
unlike that in the ligand-bound form, but similar to that
seen in the crystal structure of caspase-1 in complex
with malonate (see below). Gln385 participates in differ-
ent H-bonding interactions in the ligand-free and ligand-
bound forms of the enzyme. In ligand-free caspase-1,
Gln385 N2 forms a relatively weak H-bond with the
carbonyl oxygen of Thr334 (3.2 A˚). In the ligand-bound
form, however, Gln385 N2 interacts with the carbonyl
oxygen of Ser332 (2.8 A˚) and O1 with N1 on the Trp340
ring (3.0 A˚). It is possible that the primary function of
this loop in the ligand-free enzyme is to stabilize the
conformation of L3.
Structure of Mature Caspase-1 Containing
a Cys285→Ala Mutation in Complex
with a Malonate Molecule
We crystallized a catalytically inactive Cys285→Ala mu-
tant version of caspase-1 using 2 M sodium malonate
as the precipitant and solved its structure to 1.8 A˚ resolu-
tion (Figures 2A and 2B). The structure reveals unambig-
uous, well-defined electron density for the malonateFigure 2. A View into the Active-Site S1 Region of Human
molecule in the S1 region of the enzyme’s active siteCaspase-1 Showing Contacts between Malonate or the Aspartic
(Figure 2A) with an average B value of 22.4 for the malo-Acid Residue of an Inhibitor and Protein Atoms
nate atoms as opposed to an average B value of 21.2The S1 region of the active site in all human caspases, for which
structural information is available, shows complete primary amino for main chain and side chain atoms of the protein and
acid and three-dimensional conservation of the catalytic residues. 33.5 for water molecules.
Conserved amino acid residues involved in H bonding interactions The structure of the enzyme-malonate complex is vir-
with malonate and aspartate oxygens are labeled. H bond distances
tually identical to the structure of the enzyme complexedgreater than 3.5 A˚ (de Groot et al., 1997) are flagged in red. Broken
with a tetrapeptide inhibitor (Ac-Tyr-Val-Ala-Asp; PDByellow lines indicate distances between the protein and inhibitor
ID: 1ICE) (Wilson et al., 1994); the root-mean-squareatoms.
(A) Caspase-1 in complex with malonate (PDB ID: 1SC3; 1.8 A˚ resolu- deviation (rmsd) value for 259 C atoms of the peptide
tion). Malonate electron density from a 2Fo 	 Fc omit map contoured inhibitor-bound enzyme is 0.6 A˚ (rmsd  0.6 A˚ for 167
at 1
 level is shown in blue. C atoms of the p20 subunit, and 0.4 A˚ for 88 C atoms
(B) Residues in the P1 specificity pocket of caspase-1 (PDB ID:
of the p10 subunit). Every oxygen atom in the malonate1SC3). Electron density for the residues from a 2Fo 	 Fc omit map
molecule participates in H-bonding interactions withcontoured at 1
 level is shown in blue.
side chain or backbone atoms of residues from both(C) Caspase-1 in complex with an aspartic acid-aldehyde-based
inhibitor (PDB ID: 1ICE). p20 (5 residues: Arg179, His237, Gly238, Gln283, and
Ala285) and p10 (1 residue: Arg341) subunits in S1 and
Crystal Structure of Ligand-free Caspase-1
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appears to stabilize the dimeric protein complex. Car- mother liquor 2 days prior to data collection, reveals a
partially closed catalytic groove (Figure 1B). Althoughboxylate oxygens O5 and O7 of malonate are each
locked in place by forming three H-bonding interactions. the space group identity of the crystals did not change
following the soak, the c edge of the unit cell shrank fromO5 is stabilized by H-bonds with Arg179 N2 (2.9 A˚),
Gln283 N2 (2.9 A˚), and Arg341 N (3.2 A˚), whereas O7 a typical 160–163 A˚ seen in all other enzyme-inhibitor
cocrystal structures (all previously known crystals ofis stabilized by Arg179 N (2.7 A˚), Arg341 N2 (2.9 A˚), and
possibly His237 N1 (3.3 A˚). Both oxygens superimpose caspase-1 in complex with various inhibitors grew in
the tetragonal space group P43212) to 143 A˚. This sug-very closely on the carboxylate oxygens of the aspartic
acid residue in the tetrapeptide inhibitor (O5 corre- gested to us that parts of the protein had undergone a
structural rearrangement in the crystal. Indeed, the threesponds to Asp O2, and O7 to Asp O1; Figures 2B and
2C). Interestingly, His237 can adopt different rotamers loops that undergo conformational changes from the
ligand-free to ligand-bound form, delimited by the sameand make a lesser contribution to the H-bonding net-
work in the S1 region of the active site. For example, amino acid boundaries (285–290 in the p20 subunit, 332–
346 and 381–385 in the p10 subunit; there was no inter-the structure of the complex between caspase-1 and a
tetrapeptide inhibitor (PDB ID: 1ICE) reveals that His237 pretable electron density for residues 120–131 and 338–
345), have altered positions in the empty enzyme.N1 is likely to H-bond only to the aspartic acid carbonyl
oxygen, but not to Asp O2 (3.7 A˚). Superimposed on the structure of caspase-1 bound to a
tetrapeptide inhibitor (PDB ID: 1ICE), the core structuralOxygen O6 of the other carboxylate of the malonate
molecule H-bonds to backbone amino groups of Gly238 elements and their positions in three-dimensional space
are nearly identical, but rmsd values are relatively high(2.9 A˚) and Ala285 (2.8 A˚; the C and C of Cys285 in
the wild-type enzyme are located in the same position due to movements of the three loops. The rmsd value
for 246 C atoms of both subunits is 1.8 A˚ (rmsd 0.9 A˚as the corresponding atoms of Ala285; the S atom of
Cys285 would be situated 3.3 A˚ away from C2, 3.4 A˚ for 166 C atoms of the p20 subunit, and 2.5 A˚ for 80
C atoms of the p10 subunit). The structure reveals,from O6, and 3.6 A˚ from O4 of the malonate molecule,
easily precluding steric clashes between malonate and furthermore, that the loops did not reposition them-
selves fully to the ligand-free form observed in the truewild-type protein), while oxygen O4 forms only one H
bond with atom N1 of His237 (2.8 A˚). The C of the ligand-free enzyme (the rmsd for all the C atoms, as
well as the p20 and p10 C atoms computed separatelyAsp residue on the inhibitor is pushed closer toward the
S2 region of the active site by the bulky scaffold of from eachother, between the two set of coordinates is
close to 1 A˚), but instead found their energy minimathe inhibitor and prevents the carbonyl oxygen of the
residue from overlaying tightly O4 of malonate. This within the constraints of the crystal contacts imposed
on them by a tetragonal space group. Although we can-allows the carbonyl oxygen of the inhibitor’s Asp residue
to H-bond to N1 of His237 (2.6 A˚), but not to the amino not rule out the possibility that the S1 site of some
of the protein molecules in the crystal is occupied bynitrogen of Gly238 (4.0 A˚) as is the case with O4 of
malonate. The Asp-based inhibitors of caspase-1 lack malonate, we see neither residual density for malonate
nor density that would represent the location of thean H-bond acceptor corresponding to O6 of the malonic
acid. There appear to be no water-mediated H-bonds active-site loops consistent with some protein mole-
cules locked in a ligand-bound form and others in thein the S1 region of the active site.
There are no noticeable conformational changes be- ligand-free form. In sum, we propose that (1) the struc-
ture of the empty enzyme represents an intermediatetween a tetrapeptide- and malonate-bound caspase-1.
The most conspicuous difference in the position of side form of caspase-1, and (2) caspase-1 exists predomi-
nantly in a closed active-site conformation in the ab-chains around the active site involves Arg383. In the
structure of caspase-1 complexed with the peptidic in- sence of an S1 binding element.
hibitor, the side chain atoms of Arg383 (C, C, N, C,
N1, and N2) shift out of the way and open up the S4
Structural Rearrangements in the Central Cavityregion of the active site to accommodate the hydroxy-
at the Dimer-Dimer Interface of Caspase-1phenyl group of tyrosine; in the structure of the enzyme
The structural rearrangements that accompany ligandbound to malonate, the S4 region is closed off by a
binding also cause a significant change in the shape ofdifferent rotamer of Arg383 that involves the movement
the central cavity located at the dimer-dimer interfaceof the same atoms as those revealed in the structure
of mature caspase-1 (Figure 3). In the ligand-bound en-of the ligand-free enzyme. Taken together, the results
zyme, the cavity is fairly small, occupying a volume ofsuggest strongly that binding of malonate or a malonate-
576.6  34.4 A˚3 as computed with VOIDOO (Kleywegtlike molecule to the S1 region of the active site in casp-
and Jones, 1994). The VOIDOO-calculated volume isase-1 is necessary and sufficient to cause a conforma-
in close accordance with a volume of 495 A˚3 reportedtional change from a ligand-free to ligand-bound form,
previously for other ligand-bound forms of caspase-1or to stabilize the protein in a ligand-bound-like state.
(Mittl et al., 1997; Watt et al., 1999). Therefore, with a
substrate or an inhibitor bound to the active site, this
cavity, which could accommodate at most 43 water mol-Structure of Mature Caspase-1 Containing
a Cys285→Ala Mutation after Removal ecules, does not appear to be readily accessible to other
proteins or small molecules.of Malonate
The structure of caspase-1 crystallized in the ligand- By contrast, in the ligand-free enzyme, the central
cavity is elongated and significantly deeper, resulting inbound form in the presence of malonate, but from which
malonate was removed by transfer to a malonate-free a 5-fold expansion of the site’s volume (3252.4 
Structure
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residues that line the site’s interior in the ligand-bound
enzyme, Ile243 and Leu256, are not available for interac-
tions in the central cavity of the active-site ligand-free
enzyme.
The center of the central cavity in the ligand-bound
and ligand-free forms of caspase-1 is positioned ap-
proximately in between the C carbons of Glu390 in the
p10 subunits on the dimer-dimer interface (C-C 
5.2 A˚ in a ligand-bound form, and 4.5 A˚ in a ligand-
free form). Although the site in the ligand-free enzyme
appears to be partially closed off by the Arg240 side
chain, the electron density for this side chain is poorly
defined (average B factor 80). There is a clear electron
density for Arg240 in the ligand-bound form of the en-
zyme; Arg240 N1 may form a salt bridge with Asp338
O1 (3 A˚), and its carbonyl oxygen may be involved in
forming a water-mediated H-bond to Arg286 N. None
of the amino acids that line the central cavity in either
the ligand-bound or ligand-free form of the enzyme par-
ticipates in H-bonding interactions with a ligand. The
backbone of the catalytic residue His237 abuts the cav-
ity in the free enzyme, but the imidazole ring points away
from the site. The Asp288 side chain that lines the site in
ligand-free caspase-1 faces the active site in the ligand-
bound form of the enzyme, but does not seem to serve
as a H-bond acceptor for any atoms of the peptide-
based inhibitors (PDB ID: 1BMQ, 1IBC, 1ICE). In sum-
mary, the active site appears to be closed in the ligand-
free enzyme and the central cavity remains open, while
the reverse holds true in ligand-bound caspase-1. Thus,
there appears to be a remarkable coupling between
structural changes in the central cavity and the loop
Figure 3. The Central Cavity at the Dimer-Dimer Interface in Human rearrangements required to form a catalytically compe-
Caspase-1 tent active site.
The active site is indicated by orange ellipses; the dimer-dimer
interface is enclosed by a yellow box.
(A) Surface representation of the residues surrounding the closed Comparison of Structural Rearrangements
cavity in the enzyme complexed with an active-site inhibitor.
in Other Caspases from Ligand-Bound(B) Surface representation of the residues surrounding the open
to Ligand-free Formscavity in the active-site ligand-free enzyme.
Crystal structures of three ligand-free caspases are cur-
rently available: caspase-1 (this report), caspase-7 (Chai
et al., 2001), and caspase-9 (Renatus et al., 2001). Sur-91.9 A˚3). In principle, this expanded site could accommo-
date nearly 200 water molecules. The central cavity in prisingly, although the structural changes that occur in
several active-site loops in each of the enzymes areligand-bound, mature caspase-1 is lined by 19 amino
acids (Figure 3A; and Supplemental Figures S2A and different, the core catalytic residue atoms exclusively
from the p20 subunit remain poised to accept the aspar-S2B), while the expanded groove in the ligand-free en-
zyme is lined by 45 amino acids (Figure 3B; and Supple- tate functionality of the substrate. Residues Arg179,
His237, Gly238, Gln283, and in some cases, Cys285mental Figures S2C and S2D). These residues can be
divided into two groups presenting either backbone in the caspase-1 and -9 S1 region of the active site
(corresponding residues in caspase-7 are Arg87,atoms (Gly238, Gly242, Gln283, Cys285, Gly287, Gly291,
and Gln385 in the bound enzyme; Gly238, Ile239, Gly242, His144, Gly145, Gln184, and Cys186) are positionally
conserved. One notable exception is caspase-9, inLeu256, Cys285, and Ser332 in the ligand-free enzyme)
or side chain atoms to the cavity interior (Arg240, which the catalytic Cys285 moves 4.7 A˚ between ligand-
bound and ligand-free states of the enzyme. However,Glu241, Ile243, Gln257, Leu258, Asn259, Ile282, Ala284,
Arg286, Cys331, Pro335, Glu390, and Arg391 in ligand- the amide nitrogen of Cys285 moves from within 4.4 to
3.7 A˚ of the aspartate carbonyl oxygen (Renatus et al.,bound caspase-1, Figures 3A and 3B; His237, Ile239,
Arg240, Glu241, Cys244, His248, Gln257, Leu258, 2001) and could in principle form a stronger H-bond with
this atom of the substrate during the initial stages ofAsn259, Ala260, Phe262, Asn263, Met264, Asn266,
Lys268, Asn269, Ile282, Ala284, Arg286, Asp288, ligand binding. It remains unclear, nonetheless, if this
H-bonding interaction is required to form when a ligandSer289, Pro290, Val292, His322, Ile323, Glu324, Ala329,
Cys331, Ser332, Ser333, Thr334, Pro335, Met386, begins to enter the active site, and it appears that forma-
tion of the other H-bonds may be sufficient to causePro387, Thr388, Glu390, Arg391, and Thr393 in the
ligand-free enzyme, Figures 3C and 3D). Only two rearrangements of the active-site loops. It is also possi-
Crystal Structure of Ligand-free Caspase-1
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ble that caspase-1 and -9 exist in solution as a mixed
population of protein molecules in both ligand-bound
and ligand-free forms in the absence of a ligand. If this
is indeed the case, binding of aspartate may stabilize
the ligand-bound form of the enzyme and shift the equi-
librium toward a ligand-bound state.
Isolated mature caspase-7 is more similar to a mature
inhibitor-bound caspase-7 than it is to the procaspase-7
zymogen. In fact, the most pronounced movements take
place in loop 2 comprising the active-site Cys186 and
in the short, N-terminal stretch of amino acids of the
small subunit (residues 212–215: Lys-Ile-Pro-Val; loop
L2). Both loops are essential to the conformation of the
active site in caspase-7. Loop 2 moves slightly over the
catalytic cleft, whereas the  carbons of residues in L2
rotate 180 to form a “closed conformation” (Figure 4D)
in which the loop bundle of the active site is not properly
assembled and the active cleft is not well defined (Chai
et al., 2001). It should be mentioned that the average
temperature factors for this segment of the small subunit
are high (B factor  97.6 for residues 212–216 versus
70.4 for all protein atoms), indicating high segment flexi-
bility, and it is not quite certain whether the orientation
of this region as presented in the model is necessary
for the maintenance of a ligand-free conformation of the
protein. The movement of the N-terminal portion of the
p10 subunit in caspase-1 does not occur (Supplemental
Figure S1B), while the N-terminal segment of caspase-
9 p10 does undergo an angular shift of approximately
47 (protein aligned on residues 326–330, angle formed
by the C carbons of Leu321-Asp326-Leu321; distance
between Leu321 C in both forms of the enzyme 
10.8 A˚; Supplemental Figure S1F).
The structural rearrangements of the active-site loops
in caspase-1 bear the greatest similarity to the confor-
mational changes observed in caspase-9. The most sa-
lient feature of the transition from the ligand-free to
ligand-bound forms of both enzymes is the 180 flipping
of Arg341 from the surface of the protein into the S1
region of the active site, accompanied by a translational
shift of 11.4 A˚ in caspase-1 (Figure 1D) and 10.5 A˚ in
caspase-9. Arg341 has been implicated in substrate rec-
ognition and is conserved in all human caspases. The
movement of this polypeptide segment in both caspases
inserts Trp340 in between the S2 and S3 region of the
active site. Both segments use Pro335 and Pro343 as
pivot points on which rewinding of the loops takes place.
Figure 4. Comparison of Ligand-Bound and Ligand-free Forms of
Given high identity and similarity of residues in the loops Caspase-1, -7, and -9
that undergo conformational changes in caspase-1 and
Ligand-bound caspases are displayed as green ribbons, ligand-free
-9 and do not in caspase-7, it is surprising to realize that enzymes as purple ribbons. Small-molecule inhibitors are shown as
the active-site loops in the three caspases are subject to yellow sticks. Selected catalytic residues and residues in regions
that undergo conformational changes from ligand-free to ligand-different structural rearrangements. Our findings under-
bound forms of the enzymes are labeled white, as are the N-terminalscore the importance of structural analyses of unique
residues of the small subunits modeled in the crystal structures.forms of caspases in order to understand the mecha-
Panels show superpositions of active-site loops in ligand-free andnisms of substrate binding downstream of the binding
ligand-bound caspase dimers.
of aspartate to the S1 region of the active site. (A) Ligand-free (this report) and ligand-bound (PDB ID: 1ICE) (Wilson
et al., 1994) caspase-1 dimers. Loop 2 in the p20 subunit of
caspase-1 and loops 3 and 4 in the p10 subunit are labeled as L2,
L3 and L4, respectively.Identification of Malonate Isosteres Capable
(B) Ligand-free (PDB ID: 1F1J) (Wei et al., 2000) and ligand-boundof Protecting Caspase-1 from Autoproteolysis
(PDB ID: 1K86) (Chai et al., 2001) caspase-7.Having observed that malonate bound tightly to the S1
(C) Ligand-free (chain D) and ligand-bound (chain C) caspase-9 (PDBregion of the active site in caspase-1 crystals, we asked
ID: 1JXQ) (Renatus et al., 2001).
whether the malonate molecule would interact with the
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of the carboxylic group, and (3) the overall charge of
the compound may have an effect on the molecule’s
ability to bind to the S1 region of the active site.
The observations formed the basis of a simple assay
to look for new S1 recognition elements capable of inhib-
iting caspase-1 self-proteolysis. The assay consisted of
two steps: renaturation in the presence of a malonate/
aspartic acid isostere, and buffer exchange into a buffer
promoting the autolytic activity of the enzyme. Concen-
trating the samples to speed up autolysis followed each
step. The results of the assay are purely qualitative. We
expected that compounds which protected the enzyme
would satisfy two conditions: (1) elimination of the 7 kDa
protein band characteristic of proteolysis at Asp381 in
the small subunit of the enzyme, and (2) an improved
molar ratio of the p10 and p20 subunits due to H bonds
between the small molecules and residues from both
caspase-1 subunits that likely stabilize the p10/p20
complex. We identified 5 compounds (out of 37 tested)
that reproducibly appear to protect caspase-1 from au-
tolysis better than 99% as judged by Coomassie-stained
SDS-PAGE gels: 4-(methoxycarbonyl)nicotinic acid, thy-
mine-1-acetic acid, 1-ethyl-2,4-dioxo-1,2,3,4-tetrahy-
droquinoline-3-carboxylic acid, 2,4-dihydroxypyrimi-
dine-5-carboxylic acid, and phthalic acid monobenzyl
ester. The hallmark of these compounds is the carbox-
ylic group apt to substitute for the side chain of the
aspartic acid residue in P1, and at least one H bond
acceptor, located 3–4 atoms away from the carbon atom
Figure 5. Caspase-1 Autoproteolysis Protection Assay of the carboxylate group, that is likely to form a H bond
(A) Lane 1, marker; lane 2, input protein; lane 3, renatured unpro- with the amino groups of Gly238 and Cys285 or N1 of
tected sample; lane 4, protein plus malonate; lane 5, protein plus the catalytic residue His237.
aspartic acid; lane 6, protein plus succinic acid; lane 7, protein plus It is possible that the carboxylate group could be
4-(methoxycarbonyl)nicotinic acid; lane 8, protein plus thymine-1- replaced by another functionality that provides two
acetic acid; lane 9, protein plus 1-ethyl-2,4-dioxo-1,2,3,4-tetrahy-
H-bond acceptors in place of carboxylate oxygens. Indroquinoline-3-carboxylic acid; lane 10, protein plus 2,4-dihydroxy-
fact, compounds containing an ionizable acylsulfonam-pyrimidine-5-carboxylic acid; lane 11, protein plus phthalic acid
monobenzyl ester; lane 12, protein plus 3-carboxymethyl-quinazo- ide, a standard carboxylate replacement in P1, can inhibit
line-2,4-dione; lane 13, protein plus 2-[4-(methoxycarbonyl)-5- caspase-1 (Okamoto et al., 1999). Hydrophobic rings
methyl-2-oxo-2,3-dihydro-1H-pyrrol-3-yl]acetic acid; lane 14, pro- that serve as scaffolds for the P1 H-bond acceptors,
tein plus N-acetyl-L-tyrosine. and acceptor-distal polar groups, also determine the
(B) Structures of compounds used in the protection experiment.
compounds’ ability to form stable associations with theL1-L14 designations indicate lanes on the gel in (A) in which the
enzyme (data not shown). The small molecules identifiedcompounds were used.
in this assay are unlikely to have been identified in stan-
dard enzyme assays with caspase-1 substrates since
enzyme in solution and whether it would prevent the sodium malonate at concentrations as high as 100 mM
inactivating autoproteolysis of the p10 subunit. We dis- failed to inhibit enzyme activity in standard fluorescence
covered that at 50–100 mM concentrations, malonate assays (data not shown). Thus it appears that S1 recogni-
indeed prevented self-proteolysis (Figure 5A, lane 4). tion elements compete quite efficiently with caspase-1 as
We then asked if aspartate, the obligatory recognition a substrate of self-proteolysis, but not with small-molecule
element on all caspase substrates, was sufficient for substrates that have an inherently higher affinity for the
protection. To answer this question, we renaturated casp- active site than malonate. All in all, our protection assay
ase-1 in the presence of aspartic acid and found that offers a promising and fairly rapid method of identifying
aspartate was as efficient in protecting the enzyme from novel, non-aspartate-based P1 elements on caspase-1
autoproteolysis as malonate (Figure 5A, lane 5). We dis- small-molecule inhibitors that are likely to overcome
covered furthermore that succinate, a molecule that pharmacokinetic liabilities of the previously described
shares the aspartic acid’s spacing between the carbox- covalent compounds (Leung-Toung et al., 2002).
ylates but lacks the amino group, was inefficient at pre-
venting the self-proteolytic activity of the enzyme (Figure
5A, lane 6). These results suggested to us that (1) at Conclusions
Our analysis of a ligand-free caspase-1 reveals that theleast one carboxylate group and an additional H-bond
acceptor were required for binding to the S1 region, enzyme undergoes significant structural rearrange-
ments from a ligand-free to ligand-bound form. The(2) the additional H-bond acceptor should optimally be
located three to four atoms away from the carbon atom structure of the empty enzyme, grown in the presence
Crystal Structure of Ligand-free Caspase-1
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Table 1. Crystallographic Data and Refinement Statistics
Compound Ligand-free Malonate Soakout Malonate-Bound
PDB ID 1SC1 1SC4 1SC3
Space group P3221 P43212 P43212
Cell constants a  71.8 A˚, c  118.5 A˚ a  63.0 A˚, c  143.2 A˚ a  63.1 A˚, c  162.5 A˚
X-ray source R Axis IV R Axis IV R Axis IV
Wavelength (A˚) 1.54 1.54 1.54
Resolution (A˚) 20–2.6 20–2.1 20–1.8
Number of observations 72,417 46,239 135,413
Number of reflections 11,308 17,527 31,330
Completeness (%)a 99.6/100 96.0/78.6 97.9/94.5
Mean I/(
I )a 4.7/1.8 5.3/1.9 9.3/2.3





Model and Refinement Statistics
Resolution range (A˚) 20–2.6 20–2.1 20–1.8
Number of reflections 10,163 15,873 29,025
(1,100 in test set) (833 in test set) (1,544 in test set)
Completeness (%) 99.6 95.3 97.6
Cutoff criterion |F|  0.0 |F|  0.0 |F|  0.0
Number of residues 255 246 261
Number of water molecules 60 152 276
Rmsd bond lengths (A˚) 0.007 0.006 0.006
Rmsd bond angles () 0.979 0.911 0.845
Luzzatti error (A˚) 0.400 0.283 0.220
Correlation factorc 0.895 0.898 0.931
Rcrystd 23.06% 22.11% 20.55%
Rfree 27.27% 25.84% 23.81%
Ramachandran plot statisticse
Most favored 199 (87.7%) 197 (90.4%) 208 (90.8%)
Additional allowed 27 (11.9%) 21 (9.6%) 21 (9.1%)
Generously allowed 1 (0.4%) 0 (0%) 2 (0.9%)
Disallowed 0 (0%) 0 (0%) 0 (0%)
Overall G factor 0.0 0.1 0.2
aNumbers after forward slashes indicate high-resolution shells: ligand-free enzyme, 2.69–2.6 A˚; empty enzyme, 2.17–2.1 A˚; enzyme-malonate
complex, 1.86–1.8 A˚.
bRmerge  hkli|I(hkl)i 	 I(hkl)|/hkliI(hkl)i.
cCorrelation factor between the structure factors and the model as calculated by SFCHECK (Vaguine et al., 1999).
dRcryst  hkl|Fo(hkl) 	 Fc(hkl)|/hkl|Fo(hkl)|, where Fo and Fc are observed and calculated structure factors, respectively.
eComputed with PROCHECK (Laskowski et al., 1993).
of malonate, suggests strongly that the protein retains Our analysis of the central cavity at the dimer-dimer
interface demonstrates an intriguing reciprocal couplinga closed active site conformation in solution, due in
particular to the movement of loop 3 of the p10 subunit between structural rearrangements in the cavity and
the active site in active site-occupied and -unoccupiedto cover the catalytic groove of the enzyme and render
it inaccessible to a substrate scaffold. The crystal struc- states of the enzyme. In summary, the results presented
in this report greatly extend our knowledge of the dy-ture of caspase-1 in complex with a malonate molecule,
compared to the structure of the ligand-free enzyme, namic mechanism of substrate binding by caspase-1
as well as the structural changes that accompany theleads to an irresistible conclusion that the obligatory
aspartate recognition element on caspase ligands, transition from a ligand-free to ligand-bound form and
provide a framework for a more thorough understandingwhich consists of one carboxylic group and an addi-
tional H-bond acceptor three atoms away from the car- of this cysteine protease family.
bon atom of the carboxylate, may by itself be not only
Experimental Proceduresnecessary, but also sufficient, to cause dramatic confor-
mational changes in the active site of this class of cys-
Protein Expression and Purificationteine proteases and trap the proteins in a ligand-bound
The p20 (residues 120–297) and p10 (residues 317–404) subunits
state. This contention is supported further by the results of wild-type human caspase-1 were cloned into NdeI and EcoRI
of our work that show that wild-type caspase-1 can be restriction endonuclease sites of the pRSET plasmid (Invitrogen,
Carlsbad, CA). An active-site mutant of caspase-1 was constructedprotected from inactivating autolysis in solution equally
by site-directed mutagenesis with two complementary nucleotideswell with sodium malonate as with aspartic acid. This
(CATCATCCAGGCCGCCCGTGGTGACAGCC and GGCTGTCACCAobservation suggests, in turn, that certain malonate
CGGGCGGCCTGGATGATG) and wild-type p20 cDNA cloned in theisosteres binding to the S1 subsite conserved across
pRSET plasmid as template DNA using the QuikChange Site-
multiple caspases could become useful starting points Directed Mutagenesis Kit from Stratagene (La Jolla, CA) as recom-
for discovering selective inhibitors that exploit structural mended by the manufacturer.
Both caspase-1 subunits were expressed separately in E. colidifferences in the S2-S4 sites of this family of enzymes.
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BL21(DE3) Star cells (Invitrogen) upon induction of log-phase bacte- the probe-accessible cavity volumes computed by VOIDOO and a
solvent radius of 1.4 A˚.rial cultures with 1 mM IPTG and incubation for 4 hr at 37C. Cells
were disrupted with a microfluidizer and inclusion-body pellets col- All figures were prepared with PyMOL (DeLano, 2002).
lected by centrifuging the lysate for 30 min at 4C. The pellets were
washed 2with 50 mM Tris-HCl (pH 8), 300 mM NaCl, 1 M guanidine, Self-Proteolysis Protection Assay
and 0.1% Triton X-100 and 2 with the same buffer without the Singly expressed p10 and p20 subunits of wild-type human casp-
detergent. Washed pellets were resuspended in 6 M guanidine-HCl ase-1 were combined in a 1:1 molar ratio in 6 M guanidine HCl, and
and 20 mM DTT and frozen at 	80C. 0.5 mg aliquots in 50 l volumes were used for each renaturation
Guanidine-HCl-solubilized fractions (6 mg of p20-C285A and 3 mg experiment in 1.5 ml volume of the renaturation buffer composed
of p10) were combined in a 100 ml beaker and renatured by rapid of 100 mM HEPES (pH 8.4), 200 mM NaCl, 5% sucrose, 20 mM DTT,
dilution into 50 ml of 50 mM HEPES (pH 8), 100 mM NaCl, 1 M and 100 mM of a compound identified as a possible malonate/
nondetergent sulfobetaine 201 [NDSB-201], and 20 mM DTT. Rena- aspartic acid isostere. Renaturation was carried out for 4 hr at room
turation proceeded at room temperature for 8 hr. Samples were temperature. Samples were then centrifuged to remove the precipi-
then centrifuged in a Sorvall rotor for 30 min at 17,000 rpm to remove tant and concentrated to 100–200 l in 4 ml concentrators from
precipitates. Cleared supernatants were dialyzed extensively against VivaScience. 1.5 ml of an exchange buffer, containing 50 mM
50 mM sodium acetate (pH 5.9), 50 mM NaCl, 5% glycerol, and 4 mM CH3COONa (pH 5.9), 100 mM NaCl, 5 mM DTT, 5% glycerol, and 50
DTT overnight at 4C. Protein was concentrated to 3–5 mg/ml and mM compound, was then added to each concentrator, and samples
passed through a 0.1 m filter immediately prior to use. were concentrated for the second time to 50–100 l volumes. Rena-
tured samples were analyzed by standard SDS-PAGE to identify
compounds capable of protecting caspase-1 from autoproteolysis.Crystallization, Data Collection, and Structure Determination
Diffraction-quality crystals of ligand-free caspase-1 were obtained
Acknowledgmentsby hanging-drop vapor diffusion at 4C against a reservoir of 0.1 M
HEPES (pH 7.4), 2 M (NH4)2SO4, and 25 mM DTT. 0.01% Triton-X was
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critical reading of the manuscript and useful suggestions, and Dr.to the cover slips. Crystals of caspase-1 complexed with malonate
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preparation of the supplemental movie.tals were transferred into mother liquor composed of 0.1 M PIPES
(pH 6), 88 mM (NH4)2SO4, 25% PEG 2000 MME, 10 mM DTT, 3 mM
Received: March 11, 2004NaN3, and 2 mM MgCl2 and soaked for 2 days to remove malonate.
Revised: April 28, 2004All crystals for data collection were cryoprotected in mother liquors
Accepted: May 14, 2004supplemented with 22% (v/v) glycerol for 1–2 min and immersion
Published: August 10, 2004in liquid nitrogen (see Table 1 for space group and unit cell dimen-
sions).
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